glp-1 and protein + PDB-101: Molecule of the Month:

Endocrinology 156 , 847857 (2014)

Technical difficulties in manufacturing two separate peptide drugs or engineered dual-agonist drugs of high purity, stability, and consistency needed for subcutaneous injection make the development and commercialization of dual GLP-1/amylin combination drugs a significant manufacturing challenge

The dual GLP-1/GIP receptor agonist DA4-JC shows superior protective properties compared to the GLP-1 analogue liraglutide in the APP/PS1 mouse model of alzheimers disease

There are three GLP-1 FDA decisions expected in 2025, all for Novo Nordisks semaglutide: Ozempic for T2DM and peripheral artery disease (PAD) Wegovy SC for heart failure with preserved ejection fraction (HFpEF) and obesity The first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics talented team of clinical experts actively monitors this emerging landscape